Liquidia (NASDAQ:LQDA) Price Target Raised to $36.00

Liquidia (NASDAQ:LQDA) had its price target boosted by Scotiabank from $34.00 to $36.00 in a research report released on Monday morning, MarketBeat reports. The brokerage currently has a sector outperform rating on the stock.

Several other research firms also recently issued reports on LQDA. Needham & Company LLC reaffirmed a “buy” rating and set a $25.00 price target on shares of Liquidia in a research note on Thursday, April 10th. HC Wainwright reaffirmed a “buy” rating and set a $29.00 target price on shares of Liquidia in a research report on Thursday, March 20th. One analyst has rated the stock with a hold rating, six have issued a buy rating and two have issued a strong buy rating to the company. According to data from MarketBeat, Liquidia has a consensus rating of “Buy” and a consensus price target of $26.88.

Liquidia Trading Down 0.1 %

Shares of NASDAQ LQDA opened at $15.53 on Monday. The stock has a fifty day moving average price of $14.24 and a 200 day moving average price of $13.09. Liquidia has a 12-month low of $8.26 and a 12-month high of $16.81. The company has a market cap of $1.33 billion, a P/E ratio of -9.53 and a beta of 0.24.

Liquidia (NASDAQ:LQDA) last posted its earnings results on Wednesday, March 19th. The company reported ($0.46) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.38) by ($0.08). The company had revenue of $2.92 million during the quarter, compared to analyst estimates of $4.60 million. Liquidia had a negative net margin of 765.38% and a negative return on equity of 163.21%. On average, sell-side analysts forecast that Liquidia will post -1.51 EPS for the current fiscal year.

Insider Activity

In other Liquidia news, insider Jason Adair sold 1,856 shares of the business’s stock in a transaction on Monday, April 14th. The shares were sold at an average price of $13.57, for a total transaction of $25,185.92. Following the completion of the sale, the insider now owns 184,304 shares in the company, valued at $2,501,005.28. The trade was a 1.00 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, CEO Roger Jeffs sold 14,130 shares of the firm’s stock in a transaction dated Monday, April 14th. The stock was sold at an average price of $13.57, for a total transaction of $191,744.10. Following the completion of the transaction, the chief executive officer now owns 1,006,420 shares in the company, valued at approximately $13,657,119.40. The trade was a 1.38 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last ninety days, insiders sold 33,138 shares of company stock worth $450,233. 30.10% of the stock is currently owned by insiders.

Institutional Trading of Liquidia

A number of institutional investors and hedge funds have recently made changes to their positions in LQDA. Hurley Capital LLC bought a new stake in Liquidia in the first quarter valued at $32,000. GAMMA Investing LLC lifted its position in Liquidia by 65.6% in the 1st quarter. GAMMA Investing LLC now owns 2,961 shares of the company’s stock valued at $44,000 after purchasing an additional 1,173 shares during the last quarter. Steward Partners Investment Advisory LLC acquired a new position in Liquidia during the 4th quarter valued at about $59,000. Summit Investment Advisors Inc. grew its position in Liquidia by 35.0% in the 4th quarter. Summit Investment Advisors Inc. now owns 6,632 shares of the company’s stock worth $78,000 after purchasing an additional 1,719 shares during the last quarter. Finally, D. E. Shaw & Co. Inc. acquired a new stake in shares of Liquidia in the fourth quarter valued at approximately $142,000. 64.54% of the stock is currently owned by institutional investors and hedge funds.

About Liquidia

Liquidia Corporation, a biopharmaceutical company, develops, manufactures, and commercializes various products for unmet patient needs in the United States. Its lead product candidates include YUTREPIA, an inhaled dry powder formulation of treprostinil for the treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD).